Table 3.
Phase III studies dedicated to older patients with advanced non-small cell lung cancer.
| Author [year] | Drugs | No. patients | Response rate (%) | Median survival (months) | 1-year survival rate (%) | P |
|---|---|---|---|---|---|---|
| ELVIS [1999] | VNR | 76 | 19.7 | 6.5 | 32 | 0.03 |
| BSC | 85 | – | 4.9 | 14 | ||
| Frasci [2000] | VNR | 60 | 22 | 7 | 13 | <0.01 |
| Gem + VNR | 60 | 15 | 4.5 | 30 | ||
| Gridelli [2003] | VNR | 700 | 21 | 8.5 | 42 | ns |
| Gem | 16 | 6.5 | 28 | |||
| Gem + VNR | 18.1 | 7.4 | 34 | |||
| Kudoh [2006] | VNR | 182 | 9.9 | 9.9 | NR | ns |
| Doc | 22.7 | 14 | NR | |||
| Tsukada [2007] | Doc | 63 | ||||
| Carbo + Doc | ||||||
| Quoix [2011] | VNR or Gem | 226 | 10 | 6.2 | 25.4 | 0.0004 |
| Carbo + weekly Pacli | 225 | 27 | 10.3 | 44.5 |
Carbo, carboplatin; Doc, docetaxel; ELVIS, The Elderly Lung Cancer Vinorelbine Italian Study Group; Gem, gemcitabine; ns, nonsignificant; Pacli, paclitaxel; VNR, vinorelbine.